Atossa Therapeutics (ATOS) AI Stock Analysis

• Market Cap: $77.76M
• Dividend Yield: N/A
• Average Volume (3M): 1.16M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.09
• Revenue Growth: N/A
• EPS Growth: -9.42%
• Country: US
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 129,171,420
• 10 Day Avg. Volume: 1,949,046
• 30 Day Avg. Volume: 1,157,820
• PEG Ratio: 0.28
• Price to Book (P/B): 1.66
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.65
• Enterprise Value/Market Cap: 0.63
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -6.16K
• Enterprise Value/Ebitda: -1.53
• 1Y Price Target: $6.33
• Price Target Upside: 955.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $0.64 ▲(7.00% Upside)

The score is primarily constrained by weak financial performance (no revenue, ongoing losses and cash burn, shrinking equity) and bearish technical signals (below key moving averages with negative MACD). Positive FDA-related pipeline events provide an offset, but valuation remains pressured due to negative earnings and no dividend support.

Positive Factors

Regulatory Progress

FDA allowing the metastatic ER+/HER2- IND to proceed materially lowers regulatory execution risk for the lead program. This enables clinical data generation, supports strategic pathway clarity across indications, and strengthens the company’s ability to de-risk value drivers over coming months.

Intellectual Property

A newly issued U.S. patent with broad claims on manufacturing and enteric formulations provides durable exclusivity and formulation control. This supports lifecycle management, potential licensing or partnering, and protects commercial upside if clinical development succeeds.

Conservative Leverage

Having no meaningful debt reduces fixed obligations and lowers bankruptcy risk for a cash-burning clinical-stage biotech. This balance-sheet conservatism preserves strategic flexibility to raise equity or pursue partnerships without servicing debt, aiding multi-indication development plans.

Negative Factors

Pre-Revenue Cash Burn

Sustained negative operating cash flow and zero product revenue create a persistent financing requirement. Over 2-6 months this constrains program pacing, increases likelihood of dilutive capital raises, and can limit the company’s ability to fund multiple INDs or expansion without external financing.

Eroding Equity / Dilution Risk

Steady erosion of equity indicates cumulative losses and prior financing, implying further dilution risk to fund operations. Persistent declines reduce capital buffer, making future rounds likelier and potentially constraining long-term shareholder value if clinical milestones are delayed or unmet.

Pipeline Concentration

Heavy dependence on a single lead asset concentrates binary clinical and regulatory risk: setbacks in pivotal trials or tolerability/efficacy issues could materially impair the company’s prospects. Limited commercial diversification and a small team further heighten execution and scale-up challenges.

Atossa Therapeutics Business Overview & Revenue Model

Company Description

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

How the Company Makes Money

Atossa Therapeutics primarily generates revenue through strategic partnerships and collaborations with other pharmaceutical companies, licensing agreements, and potential milestone payments related to the development and commercialization of its drug candidates. As a clinical-stage company, revenue is also contingent upon successful clinical trial results and subsequent regulatory approvals. Additionally, Atossa may engage in fundraising activities to support its ongoing research and development efforts.

Atossa Therapeutics Financial Statement Overview

Summary

Atossa Therapeutics faces significant financial challenges, reflected in its inability to generate revenue and ongoing operational losses. While the company benefits from a debt-free balance sheet and strong equity, its cash flow situation is concerning, with negative cash flow metrics indicating reliance on external financing. The overall financial health is weak, necessitating strategic changes to improve revenue generation and operational efficiency.

Income Statement

Atossa Therapeutics has consistently reported zero revenue over the years, with increasing net losses, reflecting challenges in achieving profitability. The TTM (Trailing-Twelve-Months) data shows a worsening net loss, indicating further financial strain. The absence of revenue growth and negative profit margins highlight significant operational challenges.

Balance Sheet

The company maintains a strong equity position with no debt, which is a positive financial indicator. However, the consistent net losses and decreasing equity over time raise concerns about the sustainability of its financial position. The equity ratio remains high, suggesting financial stability despite operational losses.

Cash Flow

Atossa Therapeutics exhibits negative operating and free cash flow, indicating cash burn due to ongoing operational expenses without revenue generation. The company relies on financing activities to support operations, which may not be sustainable in the long term without revenue growth. The cash flow ratios indicate inefficiency in converting cash flow into profits, raising concerns over liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-8.00K	0.00	0.00	0.00	0.00	0.00
EBITDA	-32.28M	-27.60M	-31.35M	-27.68M	-20.50M	-14.56M
Net Income	-30.18M	-25.50M	-30.09M	-26.96M	-20.61M	-17.83M
Balance Sheet
Total Assets	58.01M	76.44M	96.25M	123.53M	141.26M	42.84M
Cash, Cash Equivalents and Short-Term Investments	51.84M	71.08M	88.46M	110.89M	136.38M	39.66M
Total Debt	0.00	0.00	0.00	0.00	0.00	18.05K
Total Liabilities	8.22M	4.97M	5.24M	5.57M	3.13M	15.68M
Stockholders Equity	49.79M	71.48M	91.02M	117.96M	138.14M	27.17M
Cash Flow
Free Cash Flow	-26.29M	-21.05M	-20.95M	-20.79M	-16.48M	-11.58M
Operating Cash Flow	-26.27M	-21.03M	-20.94M	-20.76M	-16.47M	-11.57M
Investing Cash Flow	-16.00K	-19.00K	-14.00K	-4.73M	-9.00K	-9.37K
Financing Cash Flow	3.37M	3.67M	-1.48M	0.00	113.30M	38.55M

Atossa Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATOS, the sentiment is Negative. The current price of 0.6 is below the 20-day moving average (MA) of 0.66, below the 50-day MA of 0.74, and below the 200-day MA of 0.81, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 35.99 is Neutral, neither overbought nor oversold. The STOCH value of 44.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATOS.

Atossa Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SEER	54 Neutral	$107.11M	-1.41	-25.74%	―	13.77%	-4.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OVID	51 Neutral	$117.50M	-3.23	-60.06%	―	946.61%	-11.30%
INO	46 Neutral	$112.67M	-0.63	-328.45%	―	-10.36%	42.36%
ATOS	45 Neutral	$77.76M	-2.57	-48.89%	―	―	-9.42%
AGEN	41 Neutral	$159.16M	-2.20	―	―	-33.41%	81.19%
TVGN	41 Neutral	$63.16M	-1.78	―	―	―	-234.46%

Atossa Therapeutics Corporate Events

Atossa Therapeutics outlines strategy for lead (Z)-Endoxifen program

In a recent Form 8-K, Atossa Therapeutics furnished a corporate presentation outlining its development and regulatory strategy for its lead program, (Z)-Endoxifen, including potential breast cancer indications and anticipated milestones, while specifying that the materials are not deemed filed with the SEC for liability purposes. The company cautioned that these plans are subject to significant risks and uncertainties, citing factors such as the unpredictability of preclinical and clinical results, timing and likelihood of regulatory approvals, macroeconomic conditions, capital-raising needs, and the firm’s ability to remain in compliance with Nasdaq listing standards and protect its intellectual property.

The most recent analyst rating on (ATOS) stock is a Hold with a $0.64 price target. To see the full list of analyst forecasts on Atossa Therapeutics stock, see the ATOS Stock Forecast page.

Atossa Wins FDA Clearance to Advance (Z)-Endoxifen Trial

On January 6, 2026, Atossa Therapeutics announced that the U.S. Food and Drug Administration issued a “Study May Proceed” letter for the company’s investigational new drug application to study its lead candidate (Z)-Endoxifen in metastatic ER+/HER2- breast cancer. The regulatory clearance marks a key milestone that allows Atossa to advance clinical investigation of (Z)-Endoxifen, which has shown a favorable safety profile and distinct pharmacology from tamoxifen, and may offer a treatment option for tumors resistant to other endocrine therapies, potentially strengthening the company’s position in the oncology pipeline and enhancing the strategic value of its intellectual property around (Z)-Endoxifen.

The most recent analyst rating on (ATOS) stock is a Hold with a $0.64 price target. To see the full list of analyst forecasts on Atossa Therapeutics stock, see the ATOS Stock Forecast page.

Atossa Completes FDA Meeting on Regulatory Strategies

On December 4, 2025, Atossa Therapeutics announced the completion of a Type C meeting with the FDA on November 17, 2025, to discuss regulatory strategies for advancing (Z)-endoxifen. The FDA provided feedback on potential expedited pathways for metastatic, neoadjuvant, and risk-reduction breast cancer settings, which Atossa believes will help accelerate its clinical development and regulatory review processes. This meeting marks a significant milestone for Atossa’s programs, as it aims to shorten regulatory timelines and enhance its development strategy across multiple breast cancer indications.

The most recent analyst rating on (ATOS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Atossa Therapeutics stock, see the ATOS Stock Forecast page.

Atossa Therapeutics Appoints New Chief Financial Officer

On October 14, 2025, Atossa Therapeutics announced the appointment of Mark Daniel as Chief Financial Officer, succeeding Heather Rees. Daniel’s extensive experience in finance and capital markets is expected to support Atossa’s transition from clinical development to commercialization, particularly for its (Z)-endoxifen product. His expertise in revenue forecasting, financial discipline, and capital strategy is anticipated to enhance Atossa’s operational readiness and market entry strategy.

The most recent analyst rating on (ATOS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Atossa Therapeutics stock, see the ATOS Stock Forecast page.